InvestorsHub Logo
Followers 4
Posts 383
Boards Moderated 0
Alias Born 03/18/2012

Re: ttubular post# 2797

Tuesday, 12/09/2014 11:50:53 PM

Tuesday, December 09, 2014 11:50:53 PM

Post# of 3898
PS: We have three near-term catalysts over the next five months, between now and the end of Q1/15. They are: (1) the safety data from Archexin, (2) the safety data and initial efficacy data from the Phase 1b trial with RX-3117, and (3) the safety data and initial efficacy data from an ongoing Phase 1 trial with our third candidate in development, Supinoxin.